Neuropathy Market Poised for Growth as New Therapies Target Nerve Damage

In 2025, the market size for this condition reached USD 1 billion across the seven major markets, with the United States accounting for 54% of that total. Despite the high prevalence—with approximately 1.6 million incident cases reported in 2025—current options remain limited, as there are no FDA-approved agents specifically indicated to prevent the onset of neuropathy. Patients frequently rely on off-label symptomatic care, which often fails to address the oxidative stress and neuroinflammatory processes driving the disease.

A new generation of late-stage candidates aims to fill this gap. Companies such as Averitas Pharma, Dogwood Therapeutics, and AlgoTherapeutix are leading the pipeline with therapies like Qutenza, Halneuron, and ATX01. Clinical trials are also exploring preventative interventions, including Asahi Kasei Pharma’s Recomodulin and Tarian Pharma’s TAR-0520. These developments suggest a significant transformation in the oncology supportive-care landscape, moving toward targeted neuroprotection to preserve patient quality of life.